Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, sagopilone, plus prednisone in an international trial. The research involved men with androgen-independent prostate cancer that has metastasized, meaning their cancer has spread beyond the prostate and is not longer responding to hormonal therapies.